

Steve Sisolak  
Governor  
Richard Whitley, MS  
Director



DEPARTMENT OF  
HEALTH AND HUMAN SERVICES  
Division of Health Care Financing and Policy  
*Helping people. It's who we are and what we do.*



Suzanne Bierman, JD, MPH  
Administrator

## NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

**Date of Posting:** December 12, 2019

**Date of Meeting:** January 23, 2020 at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR).

**Place of Meeting:** Hyatt Place Reno -Tahoe Airport  
1790 E. Plumb Lane  
Reno, Nevada 89502  
Phone: (775) 826-2500

**Webinar Registration:** <https://optum.webex.com/optum/onstage/g.php?MTID=e260d768575d927135883a3960784adbd>

Or go to [www.webex.com](http://www.webex.com) and enter the Event Number listed below.

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

**Event Number:** 646 050 877

Click “Join Now”

Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet.

A password should not be necessary, but if asked use: Medicaid1!

For Audio Only:

Phone: (763) 957-6300  
Event: 646 050 877

## AGENDA

1. **Call to Order and Roll Call**
2. **Public Comment on Any Matter on the Agenda**
3. **Administrative**
  - a. **For Possible Action:** Review and Approve Meeting Minutes from October 17, 2019
  - b. **Status Update by DHCFP**
    1. MSM Chapter 1200 policy update regarding recommendations from the July 25, 2019 DUR Board meeting.
    2. Addition of HHS resource link on Guide for Clinicians on the Appropriate Dosage, Reduction or Discontinuation of Long-Term Opioid Analgesics to the DHCFP Pharmacy web site, <http://dhcfnv.gov/Pgms/CPT/Pharmacy/>.
    3. Update on diabetic supply/systems policy transition from Durable Medical Equipment (DME) to Pharmacy Services benefit.
4. **Clinical Presentations**
  - a. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for multiple sclerosis (MS) agents.
    1. Public comment on proposed clinical prior authorization criteria.
    2. Presentation of utilization and clinical information.
    3. Discussion by Board and review of utilization data.
    4. Proposed adoption of updated prior authorization criteria.
  - b. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for Zelnorm (tegaserod).
    1. Public comment on proposed clinical prior authorization criteria.
    2. Presentation of utilization and clinical information.
    3. Discussion by Board and review of utilization data.
    4. Proposed adoption of updated prior authorization criteria.
  - c. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for monoclonal antibody agents.
    1. Public comment on proposed clinical prior authorization criteria.
    2. Presentation of utilization and clinical information.
    3. Discussion by Board and review of utilization data.
    4. Proposed adoption of updated prior authorization criteria.
  - d. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Nayzilam (midazolam).

1. Public comment on proposed clinical prior authorization criteria.
  2. Presentation of utilization and clinical information.
  3. Discussion by Board and review of utilization data.
  4. Proposed adoption of updated prior authorization criteria.
- e. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for narcolepsy agents.
1. Public comment on proposed clinical prior authorization criteria.
  2. Presentation of utilization and clinical information.
  3. Discussion by Board and review of utilization data.
  4. Proposed adoption of updated prior authorization criteria.

**5. Public Comment on any DUR Board Requested Report**

**6. DUR Board Requested Reports**

- a. Opioid utilization – top prescribers and members
  1. Discussion by the Board and review of utilization data.
  2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.
- b. Top opioid prescribers and top benzodiazepine prescribers
  1. Discussion by the Board and review of utilization data.
  2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.

**7. Public Comment on any Standard DUR Report**

**8. Standard DUR Reports**

- a. Review of Prescribing/Program Trends.
  1. Top 10 Therapeutic Classes for Q2 2019 and Q3 2019 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR)
  1. Review of Q3 2019.
  2. Review of Top Encounters by Problem Type.
- c. Retrospective Drug Utilization Review (RetroDUR)
  1. Status of previous quarter.
  2. Status of current quarter.
  3. Review and discussion of responses.

**9. Closing Discussion**

- a. Public comments on any subject.
- b. Date and location of the next meeting.
  - 1. Discussion of the time of the next meeting.
- c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to five minutes.

This notice and agenda have been posted at <http://dhcfp.nv.gov/> and <http://notice.nv.gov> Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least three days before the public hearing.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at [tbenitez@dhcfp.nv.gov](mailto:tbenitez@dhcfp.nv.gov) in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730.